Jiangsu Maiweikang New Drug R&D

Jiangsu Maiweikang New Drug R&D is a clinical-stage biopharmaceutical company headquartered in Nanjing, China, dedicated to the development of novel small molecule drugs. The company's research focus lies primarily in the fields of immunology and oncology, with a particular emphasis on highly selective kinase inhibitors. Its lead asset, MWK-001, is a potent and selective TYK2 inhibitor currently undergoing Phase 2 clinical evaluation for the treatment of moderate-to-severe psoriasis. By utilizing its internal drug discovery capabilities, Maiweikang aims to deliver high-quality, innovative therapies that address significant unmet medical needs in the global autoimmune and inflammatory disease markets. The company is supported by a team of experienced scientists and regional venture capital investment.